Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer,Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer,Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer,Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer

Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the
 treatment of a range of solid tumors, including cervical cancer, lung cancer,
 gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab
 was approved in China in June 2022 for use in patients with relapsed or metastatic cervical
 cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological
 data of patients with persistent, recurrent or metastatic cervical cancer treated with
 Cadonilimab were retrospectively collected, and medical images (magnetic resonance, CT, etc.)
 before and after treatment were followed up, and the efficacy was evaluated according to
 RECIST standards. The incidence and severity of adverse events and clinically significant
 abnormal laboratory test results were collected to evaluate the safety of the drug. Survival
 benefit analysis is conducted based on the patient's survival time and medical expenses.